Table 2. Univariate and multivariate predictors of event (eGFR decline > 5%) in the study population (144 patients).
|
OR (95% CI) univariate |
p-value | adjOR (95%CI) multivariate | p-value | |
|---|---|---|---|---|
| Age >45 years* | 3.0 (0.8–10.7) | 0.09 | ||
| Gender (Male) | 1.2 (0.5–2.9) | 0.66 | ||
| Smoke | 0.7 (0.3–1.6) | 0.46 | ||
| Alcohol | 1.2 (0.6–2.7) | 0.59 | ||
| Diabetes | 1.6 (0.5–5.0) | 0.45 | ||
| Hypertension | 1.4 (0.6–3.2) | 0.43 | ||
| Symptomatic cryoglobulinemia | 1.0 (0.2–4.0) | 0.99 | ||
| CDC stage B vs. A | 1.4 (0.6–3.1) | 0.44 | ||
| CDC stage C vs. A | 0.7 (0.2–2.0) | 0.50 | ||
| Grade of liver fibrosis F2 vs. F1 | 0.5 (0.1–2.2) | 0.33 | ||
| Grade of liver fibrosis F3 vs. F1 | 0.8 (0.2–4.4) | 0.83 | ||
| RBV use | 1.6 (0.6–3.7) | 0.32 | ||
| TDF use | 1 (0.4–2.4) | 0.98 | ||
| PI use | 0.4 (0.2–1.1) | 0.07 | ||
| INSTI use | 2.6 (0.9–7.3) | 0.07 | ||
| Previous HCV treatment | 0.6 (0.3–1.2) | 0.12 | ||
| BMI (<20) vs. (20–25) | 0.7 (0.2–2.4) | 0.58 | ||
| BMI 2 (>25) vs. (20–25) | 0.5 (0.2–1.2) | 0.12 | ||
| Years of HCV > 12.9* | 3.1 (1.1–8.8) | 0.03 | 2.9 (1.0–8.8) | 0.05 |
| Years of HIV > 16.9* | 2.3 (0.9–5.9) | 0.10 | ||
| CKD stage 2 vs. 1 | 0.8 (0.3–2.0) | 0.61 | ||
| CKD stage 3 vs. 1 | 1.3 (0.1–14.7) | 0.84 | ||
| Baseline CD4 < = 350* | 0.2 (0.3–1.8) | 0.16 | ||
| CD4 Nadir < 100 cells/μl | 1.3 (0.6–2.9) | 0.48 | ||
| BL HCV RNA < = 1,970,160* | 3.4 (1.3–8.8) | 0.01 | 3.5 (1.2–10.4) | 0.02 |
| PLT < = 167,000* | 4.1 (1.9–8.8) | 0.0004 | 2.8 (1.1–6.8) | 0.03 |
TDF: tenofovir; RBV: ribavirin; PI: protease inhibitors; INSTI: integrase strand transfer inhibitors; PLT: platelets; OR: odds ratio; adjOR: adjusted odds ratio; CI: confidence interval.
*Dichotomized as per ROC